372 related articles for article (PubMed ID: 31316060)
21. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
22. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome Patterns of
Arakelyan A; Melkonyan A; Hakobyan S; Boyarskih U; Simonyan A; Nersisyan L; Nikoghosyan M; Filipenko M; Binder H
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525353
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
25. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.
Prensner JR; Chen W; Iyer MK; Cao Q; Ma T; Han S; Sahu A; Malik R; Wilder-Romans K; Navone N; Logothetis CJ; Araujo JC; Pisters LL; Tewari AK; Canman CE; Knudsen KE; Kitabayashi N; Rubin MA; Demichelis F; Lawrence TS; Chinnaiyan AM; Feng FY
Cancer Res; 2014 Mar; 74(6):1651-60. PubMed ID: 24473064
[TBL] [Abstract][Full Text] [Related]
26. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
Wu C; Fan M; Hu Y
Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
[TBL] [Abstract][Full Text] [Related]
27. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
28. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
[TBL] [Abstract][Full Text] [Related]
29. Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
Falchi F; Giacomini E; Masini T; Boutard N; Di Ianni L; Manerba M; Farabegoli F; Rossini L; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Roberti M; Pellicciari R; Cavalli A
ACS Chem Biol; 2017 Oct; 12(10):2491-2497. PubMed ID: 28841282
[TBL] [Abstract][Full Text] [Related]
30. Resistance to therapy caused by intragenic deletion in BRCA2.
Edwards SL; Brough R; Lord CJ; Natrajan R; Vatcheva R; Levine DA; Boyd J; Reis-Filho JS; Ashworth A
Nature; 2008 Feb; 451(7182):1111-5. PubMed ID: 18264088
[TBL] [Abstract][Full Text] [Related]
31. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
32. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
Gornstein EL; Sandefur S; Chung JH; Gay LM; Holmes O; Erlich RL; Soman S; Martin LK; Rose AV; Stephens PJ; Ross JS; Miller VA; Ali SM; Blau S
Clin Breast Cancer; 2018 Apr; 18(2):184-188. PubMed ID: 29325860
[No Abstract] [Full Text] [Related]
33. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
35. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong LR; Gupta K; Wu AJ; Perera D; Ivanyi-Nagy R; Ahmed SM; Tan TZ; Tan SL; Fuddin A; Sundaramoorthy E; Goh GS; Wong RTX; Costa ASH; Oddy C; Wong H; Patro CPK; Kho YS; Huang XZ; Choo J; Shehata M; Lee SC; Goh BC; Frezza C; Pitt JJ; Venkitaraman AR
Cell; 2024 Apr; 187(9):2269-2287.e16. PubMed ID: 38608703
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ
Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517
[TBL] [Abstract][Full Text] [Related]
37. Identification of Somatically Acquired
Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
39. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
